Get the Stockscreener App
8.9604
4.99%
-0.4496
Cybin Inc stock is traded at $8.9604, with a volume of 224.58K.
It is down -4.99% in the last 24 hours and down -10.87% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$9.41
Open:
$9.4
24h Volume:
224.58K
Relative Volume:
0.61
Market Cap:
$188.13M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
-43.14
EPS:
-0.2077
Net Cash Flow:
$-44.93M
1W Performance:
-9.79%
1M Performance:
-10.87%
6M Performance:
-11.19%
1Y Performance:
-21.58%
1-Day Range:
$8.90
$9.63
1-Week Range:
$8.90
$10.72
52-Week Range:
$6.50
$19.85
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
8.97 | 188.13M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.43 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.62 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.54 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.75 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
HC Wainwright Forecasts Cybin's Q3 Earnings (NYSE:CYBN) - MarketBeat
What is HC Wainwright's Estimate for Cybin FY2029 Earnings? - MarketBeat
Cybin (OTCMKTS:CLXPF) Shares Up 1.9%What's Next? - MarketBeat
What is HC Wainwright's Forecast for Cybin FY2029 Earnings? - MarketBeat
How To Trade (CYBN) - Stock Traders Daily
Wall Street Analysts Believe Cybin Inc. (CYBN) Could Rally 952.23%: Here's is How to Trade - Yahoo Finance
H.C. Wainwright maintains $190 target on Cybin Inc. shares - MSN
H.C. Wainwright maintains $190 target on Cybin Inc. shares By Investing.com - Investing.com South Africa
HC Wainwright Reiterates "Buy" Rating for Cybin (NYSE:CYBN) - MarketBeat
Cybin (OTCMKTS:CYBN) Shares Up 1.8%Should You Buy? - MarketBeat
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
(CYBN) Trading Signals - Stock Traders Daily
Cybin Inc: Paradigm Changing Ambitions (NYSE:CYBN) - Seeking Alpha
Cybin enters partnership agreement to conduct phase 3 trial for depression candidate - MSN
Cybin Partners with Segal Trials for Pivotal Phase 3 Program - TipRanks
Cybin launches phase 3 trial for depression treatment - Investing.com India
Cybin launches clinical site partnerships to support PARADIGM program - TipRanks
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
Thinking about buying stock in Hanryu Holdings, Absci Corp, Spero Therapeutics, BioXcel Therapeutics, or Cybin? - Marketscreener.com
Occidental Petroleum Corp (OXY-N) QuotePress Release - The Globe and Mail
Cybin Inc. Achieves Breakthroughs in Mental Health Treatment - TipRanks
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025 - Financial Post
Jane Street Group LLC Has $204,000 Stake in Cybin Inc. (NYSE:CYBN) - Defense World
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - BioSpace
Cybin CEO to Present at Lytham Partners Healthcare Summit: Mental Health Innovation Spotlight - StockTitan
Cybin (OTCMKTS:CLXPF) Trading 5.4% Higher – Time to Buy? - Defense World
BUSINESS WIRE NEWS RELEASES - Wallaceburg Courier Press
Cybin (OTCMKTS:CYBN) Trading Down 2% – Here’s What Happened - Defense World
Learn to Evaluate (CYBN) using the Charts - Stock Traders Daily
Cybin (NYSE:CYBN) Stock Price Up 1%Here's Why - MarketBeat
Objective long/short (CYBN) Report - Stock Traders Daily
Cybin (FRA:R7E) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
Facet Life Sciences Partners with Cybin to Advance Mental Health Therapies - MSN
Cybin Reveals Promising Results in Depression Treatment - TipRanks
Cybin's Breakthrough Clinical Data Shows 100% Response Rate in Depression Treatment Study - StockTitan
(CYBN) Investment Report - Stock Traders Daily
PEAK6 Investments LLC Sells 420,512 Shares of Cybin Inc. (NYSE:CYBN) - MarketBeat
Cybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish - MSN
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 - Chatham-Kent This Week
Cybin to Discuss Breakthrough Treatments at Fireside Chat - TipRanks
TANG CAPITAL MANAGEMENT LLC Increases Stake in Cybin Inc - GuruFocus.com
Psychedelic Drugs Market Growth in Future Scope 2024-2031 | - openPR
Cybin (FRA:R7E) 3-Year EPS without NRI Growth Rate : 6.10% (As of Sep. 2024) - GuruFocus.com
Cybin (FRA:R7E) 50-Day SMA : €9.05 (As of Nov. 30, 2024) - GuruFocus.com
Cybin (OTCMKTS:CYBN) Stock Price Down 4.3%What's Next? - MarketBeat
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
Cap:
|
Volume (24h):